Anzeige
Mehr »
Sonntag, 20.09.2026 - Börsentäglich über 12.000 News
Breaking News: NurExone im Vollgas-Modus!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
243 Leser
Artikel bewerten:
(1)

Conagen unveils commercial production of high-purity non-GMO salidroside

Ideal for adaptogen supplement solutions and natural preservatives in food and beverages.

Bedford, Mass., Sept. 27, 2022announced the commercialization of its 99% high-purity salidroside made by bioconversion technology, an active ingredient from the herbal plant Rhodiola rosea (golden root). Its strong antioxidant properties as an adaptogen are associated with reducing inflammation, protecting against oxidative stress in cells, and providing relief from depression, fatigue, and stress. Salidroside has also been used to alleviate high altitude sickness.

Unlike other salidroside products currently on the market, Conagen's salidroside is non-GMO. Conagen leveraged its industry-leading bioconversion technology to produce clean, sustainable salidroside, identical to the compound naturally found in the Rhodiola rosea plant --- the same technology used to produce non-GMO Rebaudioside M, other steviol glycosides, and bitter blockers for sugar reduction solutions which are available from their pipeline partner, Sweegen.

Conagen's 99% high-purity salidroside, made by bioconversion, is ideal for non-GMO supplement solutionsto formulate products with a sustainable and natural consumer appeal. It is readily soluble in water and is very formulable in food and beverage applications.

"We're reimagining the way in which rare ingredients are sourced to make them safer and higher-quality for use in health-promoting products," said Casey Lippmeier, Ph.D., senior vice president of innovation at Conagen. "Our bioconversion technology enables us to deliver non-GMO products. Through this technology, we're unlocking salidroside's great potential as a powerful active health ingredient and as a tool for food and beverage producers to adopt a more natural way to preserve food and beverages."

Food and beverage producers benefit from Conagen's salidroside as it also possesses antimicrobial properties, making it useful as a natural preservative solution for brands seeking alternatives to artificial preservatives. Salidroside expands Conagen's portfolio of natural preservatives, such as Taxifolin BC-DHQ and Rosavel rosmarinic acid, currently available from another pipeline partner, Blue California.

Stress reduction is popular among consumers, typically addressed by exercise or indulgence in food and beverages. More consumers are taking a holistic approach to their health, including their mental well-being and sleep. They are exploring adaptogens as one of the additional positive ways to add an edge to their diets and lifestyles.

"Salidroside is one of the rare, natural molecules with proven adaptogenic activities which correlates to stress reduction," said Lippmeier. "Initially identified in botanical extracts, adaptogens are promising new options in the quest to relieve the stress of our daily lives. This trend opens new opportunities for supplement brands and food and beverage manufacturers to adopt a health-focused profile for their products."

Conagen accelerated salidroside production by leveraging one of its proprietary molecular platforms, which have also been used to produce the clean antioxidants hydroxytyrosoland p-coumaric acid. Salidroside is a glucoside of tyrosol. Conagen's antimicrobial and antioxidant compounds, hydroxytyrosol and p-coumaric acid are also now available through Blue California.

The inputs of fermentation are tightly controlled, dramatically reducing the chance of contamination with heavy metals, fungal toxins, and other unsafe materials that may be found in traditional medicine preparations. Rhodiola rosea extract is most commonly used in Europe and Asia. Its medicinal use for reducing stress and depression can be traced back to the Ming Dynasty in the classic medicinal scripture Compendium of Materia Medica.

###

About Conagen

We're making the impossible possible. Conagen is a product-focused synthetic biology R&D company with large-scale manufacturing capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and bioconversion technologies. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachments

  • Conagen's salidroside, an active ingredient from Rhodiola Rosea (https://ml.globenewswire.com/Resource/Download/8fbd2342-c98d-47b2-a720-2bb3cc277739)
  • Unlike other salidroside products currently on the market, Conagen's salidroside is non-GMO. (https://ml.globenewswire.com/Resource/Download/76521fda-e580-488d-aa5c-4189fd67e9ac)

© 2022 GlobeNewswire (Europe)
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.